QUALITY POLICY

Microviable Therapeutics is a spin-off of the Dairy Research Institute of Asturias (IPLA-CSIC), member of the National Research Council (CSIC). Microviable has ensembled a multidisciplinary team of scientists with expertise in the field of intestinal microbiota and human health, coupled with management team with strong experience in different pharmaceutical companies. In addition, we have numerous collaborators in different hospitals, universities, and research centers internationally.

Microviable Therapeutics is developing a novel class of biological products based on defined bacterial consortia (Live biotherapeutic products, LBPs) with therapeutic applications in neurological and skin disorders. In parallel, Microviable is working on next generation probiotics personalized for specific targeted population, currently focused on sports performance and healthy ageing.

The pillars on which Microviable Therapeutics is based are fundamentally:

• The close relationship with the IPLA, CSIC and the University of Oviedo in R&D activities.

• The medical devices for *in vitro* diagnosis and related services are
safe, reliable and comply with applicable specifications, standards and legislation.

• The microbiota storage services guarantee the safe conservation of the sample, applying rigorous quality controls both in its initial preparation and in the freezing phase.

• Proximity to our stakeholders and exhaustive analysis of their needs and expectations in order to provide a prestigious service.

• The achievement of excellent working conditions and environment enabling high satisfaction of our multidisciplinary team.

• Improving the quality of health products and services provided by analyzing data and identifying areas for improvement, collaborating jointly with the stakeholders involved.

We pursue continuous improvement of our processes and the maintenance of a Quality Management System in accordance with the requirements established by the UNE-EN ISO 9001 standard (Quality management systems, requirements) and the UNE-EN ISO 13485 standard (Medical devices, Quality management systems, requirements for regulatory purposes), whose scope is defined as *"Design, manufacture and marketing of medical devices for in vitro diagnosis (Kit for the collection and transfer of fecal material in anaerobic conditions, GutAlive®). Processing and storage of human intestinal microbiota" and "Design, manufacture and marketing of medical devices for in vitro diagnosis (Kit for the collection and transfer of fecal material under anaerobic conditions)",* respectively.

This quality policy is reviewed at least once a year, it is disseminated through its publication on the Microviable Therapeutics website and provides the reference framework for establishing quality objectives.

In Gijón (Asturias), on April 24th, 2023

MicroViable therapeutics
CIF: B52543642